---
title: "Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292529312.md"
description: "Vertex Pharmaceuticals (VRTX) shares fell 1.06% to $480.25 on Monday, marking its fifth consecutive day of losses and closing 10.01% below its 52-week high. The decline occurred during a broad market downturn, with the S&P 500 down 0.79%. While competitors like AbbVie and Krystal Biotech also saw minor declines, Arcturus Therapeutics dropped significantly by 3.73%, highlighting Vertex's underperformance relative to some peers despite the general negative sentiment."
datetime: "2026-07-13T20:37:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292529312.md)
  - [en](https://longbridge.com/en/news/292529312.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292529312.md)
---

# Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 1.06% to $480.25 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.79% to 7,515.34 and Dow Jones Industrial Average falling 0.26% to 52,498.64.

This was the stock's fifth consecutive day of losses.

Vertex Pharmaceuticals Inc. closed 10.01% short of its 52-week high of $533.67, which the company achieved on July 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as AbbVie Inc. (ABBV) fell 0.03% to $248.00, Krystal Biotech Inc. (KRYS) fell 0.65% to $363.44, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 3.73% to $6.71.

Data source: Dow Jones Market Data, FactSet. Data compiled July 13, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-13-26 1637ET

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)

## Related News & Research

- [Carmignac Gestion Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/294662029.md)
- [VRTX: Q2 2026 revenue up 12% to $3.33B; full-year guidance raised; Crinetics acquisition pending](https://longbridge.com/en/news/294732107.md)
- [Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance](https://longbridge.com/en/news/294733893.md)
- [CRNX: Vertex acquisition announced as PALSONIFY drives Q2 revenue surge amid ongoing pipeline progress](https://longbridge.com/en/news/294732893.md)
- [Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases](https://longbridge.com/en/news/294966190.md)